Sanofi (SNY)
(Delayed Data from NSDQ)
$46.97 USD
+0.11 (0.23%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $46.98 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Sanofi has a PEG ratio of 1.22 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.56.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNY 46.97 +0.11(0.23%)
Will SNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Other News for SNY
Sanofi’s Tzield Gains Approval in China for Type 1 Diabetes
Former CDC Director Monarez says RFK Jr. fired her for not following two directives
Technical picture remains unchanged for SNY after it rises 0.51% on September 16
Berenberg Bank Sticks to Its Buy Rating for Sanofi (SNYNF)
J.P. Morgan Keeps Their Buy Rating on Sanofi (SNYNF)